Microsoft To Rally Over 20%? Here Are 10 Top Analyst Forecasts For Thursday
Portfolio Pulse from Avi Kapoor
Top Wall Street analysts have updated their price targets and ratings for several US-listed companies. Keybanc raised Netflix's target to $525, JP Morgan increased Karuna Therapeutics' target to $330 but downgraded it to Neutral, Canaccord Genuity raised MicroStrategy's target to $791, HC Wainwright & Co. upped Zevra Therapeutics' target to $15, Needham increased Freshworks' target to $30, Mizuho raised Ball Corporation's target to $62, Truist Securities lifted NIKE's target to $111, Benchmark increased Nova's target to $150, Wedbush raised Microsoft's target to $450, and Raymond James upped Cytokinetics' target to $92. The changes reflect analysts' optimism or updated assessments of these companies' future prospects.
December 28, 2023 | 1:36 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Mizuho increased Ball Corporation's price target from $60 to $62 and maintained a Neutral rating.
The slight increase in price target is positive, but the Neutral rating suggests that the short-term impact on the stock price may be limited.
CONFIDENCE 75
IMPORTANCE 60
RELEVANCE 70
NEUTRAL IMPACT
JP Morgan raised Karuna Therapeutics' price target from $217 to $330 but downgraded the stock from Overweight to Neutral.
The raised price target indicates a positive view on the company's value, but the downgrade to Neutral may temper investor enthusiasm, likely resulting in a neutral short-term impact.
CONFIDENCE 75
IMPORTANCE 70
RELEVANCE 80
NEUTRAL IMPACT
Truist Securities lifted NIKE's price target from $107 to $111 and maintained a Hold rating.
The increase in NIKE's price target is a positive sign, but the Hold rating indicates a neutral short-term impact on the stock price.
CONFIDENCE 75
IMPORTANCE 65
RELEVANCE 75
POSITIVE IMPACT
Raymond James upped Cytokinetics' price target from $63 to $92 and maintained an Outperform rating.
The substantial increase in price target and the Outperform rating reflect a strong positive outlook for Cytokinetics, which could positively impact the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 85
RELEVANCE 90
POSITIVE IMPACT
Needham raised Freshworks' price target from $25 to $30 and maintained a Buy rating.
The raised price target and Buy rating indicate a positive outlook for Freshworks, which may lead to a short-term increase in the stock price.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 85
POSITIVE IMPACT
Wedbush raised Microsoft's price target from $425 to $450 and maintained an Outperform rating.
The increased price target and positive rating from Wedbush indicate a bullish outlook for Microsoft, potentially leading to a short-term stock price increase.
CONFIDENCE 85
IMPORTANCE 85
RELEVANCE 90
POSITIVE IMPACT
Canaccord Genuity increased MicroStrategy's price target from $670 to $791 and maintained a Buy rating.
The significant raise in price target and the maintenance of a Buy rating could lead to a positive short-term impact on MicroStrategy's stock price.
CONFIDENCE 85
IMPORTANCE 85
RELEVANCE 90
POSITIVE IMPACT
Keybanc raised Netflix's price target from $510 to $525 and maintained an Overweight rating.
The increase in price target by Keybanc suggests a positive outlook for Netflix, which could lead to a short-term increase in the stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90
POSITIVE IMPACT
Benchmark raised Nova's price target from $125 to $150 and maintained a Buy rating.
The raised price target and Buy rating suggest a strong positive sentiment towards Nova, which could lead to a short-term rise in its stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 85
POSITIVE IMPACT
HC Wainwright & Co. raised Zevra Therapeutics' price target from $10 to $15 and maintained a Buy rating.
The increase in price target and continued Buy rating suggest confidence in Zevra Therapeutics' potential, which could positively influence its stock price in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 85